Why the study?
Does the use of glycoprotein IIb/IIIa inhibitors affect in-hospital complications and overall management costs in patients with STEMI undergoing primary PCI?
Observational (n=294)
No
Does the use of glycoprotein IIb/IIIa inhibitors affect in-hospital complications and overall management costs in patients with STEMI undergoing primary PCI?
Absolute Event Rate: 2.7% vs 4.4%
p-value: p=0.76
In real-world STEMI patients undergoing primary PCI, selective use of glycoprotein IIb/IIIa inhibitors did not increase in-hospital complications, though abciximab was associated with significantly higher costs compared to small molecules or no GPI.
Does not support routine glycoprotein IIb/IIIa inhibitor use in primary PCI; leaves open efficacy in selected high-risk subgroups.
Associated to primary percutaneous coronary intervention (pPCI), pharmacotherapy in acute ST-Segment elevation myocardial infarction (STEMI) patients have transformed the management of the acute phase. Use of glycoprotein IIb/IIIa inhibitors (GPI) remains debatable, level of guidelines has been modified in the successive editions of guidelines. In the latest European Society of Cardiology guidelines, GPI have a IIb B level in upstream use and IIa C in bail out during pPCI procedure. In front of the varying recommendations, we analysed clinical characteristics of patients with ST-Segment elevation myocardial infarction according to the use of GPI. We evaluate complications during hospitalization, particularly bleeding events. The cost of patients' management was also analysed.
No takes yet. Share an insight, caveat, or question.
Cuny et al. (2018) conducted an observational in Acute ST-Segment Elevation Myocardial Infarction (STEMI) (n=294). Glycoprotein IIb/IIIa inhibitors vs. No Glycoprotein IIb/IIIa inhibitors was evaluated on In-hospital mortality (p=0.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: